A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Clinical trial NCT01059630 · COMPLETED
Trial details
- NCT number
- NCT01059630
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-04-30
- Primary completion
- 2014-09-30
- Enrollment
- 413
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.